Leo Pharma absorbs scrapped innovation hubs to streamline focus

Leo Pharma’s decision to integrate three previously external innovation hubs in Boston, Tokyo and Shanghai stems from a wish to bring activities closer to its own R&D division. According to Head of R&D Jörg Möller, the company is now only betting in areas where it has a competitive edge and can win.
Leo Pharma's head of research and development, Jörg Möller, will still have to keep track of three development hubs across the US and Asia, despite the organization at large refocusing its internal R&D | Photo: MAGNUS MØLLER
Leo Pharma's head of research and development, Jörg Möller, will still have to keep track of three development hubs across the US and Asia, despite the organization at large refocusing its internal R&D | Photo: MAGNUS MØLLER
by ulrich quistgaard, translated by daniel pedersen

Leo Pharma previously reported that its three external innovations hubs were to close, but this isn’t entirely the case. Going forward, the units will become part of Leo Pharma’s internal research organization, according to Jörg Möller, head of global research and development at Leo Pharma.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading